| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥247.3B | ¥198.3B | +24.7% |
| Operating Income | ¥23.6B | ¥22.9B | +3.2% |
| Ordinary Income | ¥21.4B | ¥28.0B | -23.7% |
| Net Income | ¥22.7B | ¥18.4B | +23.3% |
| ROE | 10.4% | 9.7% | - |
FY2025 results: Revenue 247.3B yen (YoY +24.7%), Operating Income 23.6B yen (+3.2%), Ordinary Income 21.4B yen (-23.7%), Net Income 22.7B yen (+23.3%). Revenue grew strongly for the period driven by expansion across all three reporting segments, with the largest contribution from Elderly Care Related segment at 88.9B yen. Operating income increased modestly at +3.2% despite the 24.7% revenue growth, indicating margin compression. The decline in ordinary income from 28.0B to 21.4B yen reflects increased interest expenses of 3.4B yen due to elevated debt levels. Net income exceeded prior year by 23.3% supported by extraordinary gains of 10.3B yen, primarily from asset disposals totaling 8.5B yen. Operating cash flow turned negative at -18.8B yen compared to prior year positive territory, representing a deterioration of 244.5% YoY and raising concerns about earnings quality and working capital management.
Revenue increased 49.0B yen to 247.3B yen, reflecting growth across all three reporting segments. Comprehensive Medical Management Support contributed 77.3B yen (segment revenue YoY +21.4%), Specially Controlled Medical Device 74.6B yen (+14.0%), and Elderly Care Related 88.9B yen (+29.5%). The Other segment expanded significantly to 6.6B yen from 0.6B yen, reflecting growth in treatment data analysis services. Gross profit margin stood at 42.6% with gross profit of 105.4B yen, while SG&A expenses totaled 81.7B yen representing 33.0% of revenue. The combination resulted in operating income of 23.6B yen with operating margin of 9.6%, down 2.0 percentage points from the prior year's 11.6%, indicating that revenue growth was accompanied by proportionally higher operating expenses. Operating income growth of only 3.2% compared to 24.7% revenue growth confirms material margin compression, likely attributable to corporate overhead allocation of 13.8B yen and goodwill amortization of 2.0B yen.
Non-operating income totaled 1.4B yen while non-operating expenses reached 3.6B yen, resulting in net non-operating loss of 2.2B yen. Interest expenses of 3.4B yen increased substantially from prior period levels due to expanded borrowings, with total interest-bearing debt reaching 206.8B yen. This interest burden drove the 23.7% decline in ordinary income despite modest operating income growth. The divergence between operating income (23.6B yen) and ordinary income (21.4B yen) reflects a 9.3% reduction due to financial costs.
Extraordinary gains of 10.3B yen, primarily comprising gains on sale of fixed assets of 8.5B yen, elevated profit before tax to 30.9B yen. After income tax expense of 2.1B yen and non-controlling interests of 1.0B yen, net income attributable to owners reached 22.7B yen. The effective tax rate of 6.8% appears unusually low, suggesting potential tax benefits or deferred tax adjustments. Extraordinary items contributed approximately 33.4% of profit before tax, indicating material reliance on non-recurring factors for reported profitability.
This represents a revenue up/profit mixed pattern, where strong top-line expansion was offset by margin deterioration at the operating level, elevated financial costs compressing ordinary income, and reliance on asset disposal gains to support net income growth.
Comprehensive Medical Management Support generated revenue of 77.3B yen with operating income of 24.5B yen, achieving the highest margin among segments at 31.7%. This segment serves as the core business with the strongest profitability profile, contributing 32% of operating income despite representing 31% of total revenue. Year-over-year revenue grew 21.4% with operating income increasing from 28.0B yen to 24.5B yen, representing a decline of 12.5%. The margin contracted from prior year levels, suggesting increased investment in personnel, digital transformation support services, or other cost structure expansion.
Specially Controlled Medical Device reported revenue of 74.6B yen with operating income of 5.2B yen, yielding a 7.0% margin. This segment encompasses contact lens manufacturing and distribution. Revenue advanced 14.0% from the prior year's 65.4B yen while operating income increased from 4.8B yen to 5.2B yen, representing 8.3% growth. The relatively stable margin indicates consistent cost management despite manufacturing and distribution challenges.
Elderly Care Related recorded revenue of 88.9B yen with operating income of 5.3B yen at a 6.0% margin, representing the largest segment by revenue at 36% of total but with the lowest profitability. Revenue expanded 29.5% from 68.7B yen driven by nursing home operations and facility referral services. Operating income improved significantly from 3.1B yen to 5.3B yen, up 71.3%, demonstrating operational leverage as scale economies emerge in facility operations. This segment shows improving unit economics as occupancy rates and operational efficiency advance.
The Other segment contributed 6.6B yen in revenue with operating income of 2.4B yen at a 36.4% margin, though prior year showed negative profitability. This includes treatment data analysis services and represents an emerging growth area with improving economics. Total segment profit before corporate allocation was 37.4B yen, from which 13.8B yen of unallocated corporate costs reduced consolidated operating income to 23.6B yen. The increasing corporate cost base relative to operating segment profits warrants monitoring as the company scales.
[Profitability] ROE of 10.4% reflects adequate return on equity though heavily influenced by financial leverage of 2.99x. Operating margin of 9.6% declined 2.0 percentage points from prior year's 11.6%, indicating margin compression as revenue growth outpaced profit expansion. Net profit margin of 9.2% benefited from extraordinary gains contributing 33.4% of pre-tax profit, suggesting underlying recurring margin is approximately 6.1% when adjusted for asset disposal gains. Gross margin of 42.6% remained stable, implying the margin pressure originated from SG&A expenses growing faster than revenue. [Cash Quality] Cash and deposits totaled 90.9B yen with short-term investments of 2.0B yen, providing cash coverage of short-term liabilities at 2.16x. However, operating cash flow deteriorated to -18.8B yen, representing -68% conversion of net income and raising material concerns about earnings quality and working capital efficiency. Days sales outstanding extended to approximately 79 days based on receivables of 53.4B yen against annualized revenue, indicating slower collection cycles. [Investment Efficiency] Total asset turnover of 0.38x reflects capital-intensive operations with property, plant and equipment of 317.3B yen representing 48.7% of total assets, primarily nursing facilities and medical equipment. Goodwill of 23.5B yen increased 178.8% YoY, suggesting recent M&A activity requiring monitoring for impairment risks. [Financial Health] Equity ratio of 33.4% provides moderate capitalization though declining from 31.5% as debt grew faster than equity. Total interest-bearing debt of 206.8B yen yielded Debt/EBITDA of 6.21x, substantially exceeding the 4.0x threshold and indicating elevated leverage. Current ratio of 216.7% and quick ratio of 207.9% demonstrate adequate short-term liquidity despite negative operating cash flow.
Operating cash flow of -18.8B yen deteriorated significantly from positive territory in the prior period, driven by operating profit adjustments totaling -2.9B yen before working capital changes. Working capital absorbed substantial cash with receivables increasing 16.3B yen, inventories rising 7.8B yen, and payables declining 3.2B yen, collectively consuming approximately 27.3B yen. Income taxes paid of 10.3B yen and interest paid of 6.0B yen further pressured operating cash generation. The operating CF to net income ratio of -0.68x indicates earnings are not converting to cash, with significant quality concerns around accruals and working capital management. Investing cash flow of -22.2B yen comprised capital expenditures of 9.2B yen and likely acquisitions given the 178.8% increase in goodwill. Free cash flow of -41.0B yen reflects substantial cash consumption requiring external financing. Financing cash flow of positive 17.8B yen indicates the company raised capital through debt to fund operations and investments, with short-term borrowings increasing 25.5B yen to 42.1B yen. The dependency on external financing to cover negative operating and investing cash flows creates refinancing risk if cash generation does not improve. Cash and deposits increased modestly despite negative free cash flow due to the financing inflow, though this financing-dependent model is unsustainable without operational cash flow recovery.
Ordinary income of 21.4B yen versus operating income of 23.6B yen reflects net non-operating expense of 2.2B yen, primarily interest expense of 3.4B yen offset partially by interest and dividend income of 0.5B yen. Non-operating items represent 0.9% of revenue and consist predominantly of financing costs associated with the 206.8B yen debt balance. Extraordinary gains of 10.3B yen, comprising 8.5B yen from asset disposals and other gains, materially enhanced pre-tax profit to 30.9B yen from ordinary income of 21.4B yen. These non-recurring items represent 33.4% of profit before tax, indicating that approximately one-third of reported pre-tax earnings derive from asset sales rather than core operations. Adjusting for extraordinary items, recurring pre-tax profit approximates 20.6B yen, yielding a recurring net margin of approximately 6.1% versus reported 9.2%. Operating cash flow of -18.8B yen significantly trails net income of 22.7B yen, with OCF/NI ratio of -68%, signaling material earnings quality concerns. The negative cash conversion primarily stems from working capital deterioration, with receivables increasing 58.7% and days sales outstanding extending to 79 days. Accruals quality appears weak as profit growth is not accompanied by commensurate cash generation, suggesting either aggressive revenue recognition, working capital mismanagement, or fundamental business model challenges in converting earnings to cash. The combination of extraordinary income dependency and negative operating cash flow indicates earnings quality warrants significant scrutiny, with sustainable earnings power materially below reported figures.
Full-year guidance projects revenue of 330.4B yen, operating income of 28.6B yen, and ordinary income of 26.5B yen. Current period achievement rates stand at revenue 74.9%, operating income 82.7%, and ordinary income 80.7% against full-year targets. These progress rates exceed the standard 75% benchmark for nine-month equivalent achievement, suggesting the company is tracking ahead of plan at the consolidated level. Revenue guidance implies Q4 contribution of 83.1B yen representing 25.1% of full-year revenue, slightly above quarterly average and indicating expected seasonal strength or M&A consolidation effects. Operating income forecast implies Q4 contribution of 5.0B yen at 17.5% of annual target, below proportional run rate and suggesting either conservative guidance or expected margin pressure in the final quarter. The 21.1% YoY growth target for operating income significantly trails the 33.6% revenue growth target, confirming management's expectation of continued margin compression into FY2025. Ordinary income growth target of 23.9% exceeds operating income growth despite elevated interest expense, implying assumption of reduced financing costs or improved non-operating performance in Q4. EPS forecast of 46.41 yen appears inconsistent with net income guidance, suggesting potential share count changes or calculation adjustments. The absence of dividend forecast (0.00 yen) indicates continuation of no-payout policy to preserve cash for growth investments and working capital requirements. Forecast assumptions note that achievement depends on integration progress of acquired entities, realization of operational synergies, and stabilization of working capital cycles, with actual results subject to material variation based on M&A execution and healthcare reimbursement policy changes.
Annual dividend forecast is 0.00 yen, representing continuation of no-dividend policy with no payout to shareholders from current period earnings. Payout ratio is 0% as the company retains all earnings for internal reinvestment and working capital requirements. No share buyback activity was disclosed during the period. Total return ratio stands at 0% with no cash distributions to shareholders through either dividends or repurchases. The zero payout policy reflects management's strategic priority to allocate capital toward growth investments, M&A activities, and balance sheet strengthening given the elevated leverage profile with Debt/EBITDA of 6.21x. Free cash flow of -41.0B yen further constrains distribution capacity, as the company consumed substantial cash from operations and investments requiring external financing to maintain liquidity. The accumulation of retained earnings to 120.2B yen provides internal capital for future deployment, though the negative operating cash flow indicates this book equity is not accompanied by liquid resources. Shareholders receive no current income return and depend entirely on capital appreciation driven by growth execution and eventual cash flow normalization. The shareholder return profile carries elevated risk given the financing-dependent business model and working capital challenges, with dividend resumption contingent upon achieving sustainable positive operating cash flow and debt reduction to more manageable levels below 4.0x Debt/EBITDA.
Healthcare reimbursement policy changes present material revenue risk as Comprehensive Medical Management Support (31% of revenue) and Elderly Care Related (36% of revenue) segments depend on government-regulated fee structures and insurance coverage. Revisions to medical and long-term care insurance reimbursement rates directly impact facility economics and consulting demand, with potential impact quantified at 10-15% of segment revenues based on historical policy adjustments. Probability is moderate given ongoing fiscal pressures on Japan's social insurance systems.
Working capital deterioration and cash conversion failure represent immediate financial risk with operating cash flow of -18.8B yen and days sales outstanding of 79 days indicating collection challenges. Receivables increased 58.7% to 53.4B yen, growing substantially faster than revenue at 24.7%, suggesting either extended payment terms to win business or actual collection difficulties. If working capital efficiency does not improve, the company faces liquidity strain requiring additional debt financing or equity raises. Probability is high given current trajectory, with potential impact of 20-30B yen additional financing needs over the next 12 months.
High leverage with Debt/EBITDA of 6.21x creates refinancing risk and interest rate sensitivity with 206.8B yen of interest-bearing debt incurring 3.4B yen annual interest expense. Short-term borrowings increased 153.0% to 42.1B yen, requiring rollover or repayment within 12 months. If operating cash flow remains negative and lenders reduce credit availability or increase pricing, the company faces potential covenant violations or funding gaps. Rising interest rates would directly pressure profitability, with each 100 basis point rate increase potentially reducing ordinary income by approximately 2.1B yen. Probability is moderate to high given weak cash generation and elevated debt metrics, with material impact on financial flexibility and cost of capital.
[Industry Position] (Reference - Proprietary Analysis)
The company operates across healthcare support services, medical device manufacturing, and elderly care facility operations, spanning multiple industry classifications within the broader healthcare and social assistance sector. Limited directly comparable benchmark data is available given the diversified business portfolio. Profitability metrics show operating margin of 9.6% and ROE of 10.4%, which position at the median to lower range for integrated healthcare services providers in Japan, where specialized segments typically achieve 12-15% operating margins and ROE of 12-18%. The margin compression from 11.6% to 9.6% represents underperformance relative to sector trends. Financial health indicators with equity ratio of 33.4% fall below the industry median of approximately 45-50% for comparable healthcare services firms, reflecting more aggressive leverage strategy. Debt/EBITDA of 6.21x substantially exceeds typical healthcare services leverage of 2.0-3.5x, indicating elevated financial risk relative to peers. Efficiency metrics show asset turnover of 0.38x reflecting the capital-intensive nature of facility operations, comparable to elderly care operators but below medical device and consulting segments which typically achieve 0.8-1.2x. Cash conversion efficiency with negative operating cash flow and OCF/NI of -68% significantly underperforms industry standards where healthcare services typically maintain 80-120% cash conversion ratios. The combination of adequate ROE, compressed margins, elevated leverage, and weak cash generation positions the company in the lower quartile of financial performance relative to healthcare services benchmarks. Industry context suggests the company is pursuing aggressive growth through M&A and expansion ahead of operational maturity, accepting near-term margin pressure and leverage elevation to capture market share, though this strategy carries execution risk if integration and cash flow normalization do not materialize as planned.
Revenue growth trajectory of 24.7% significantly outpaces typical healthcare services sector growth of 5-8%, driven by M&A expansion and segment diversification into elderly care and medical management support. The company demonstrates strong top-line momentum with all three major segments contributing double-digit growth, indicating successful market share capture and demographic tailwinds from Japan's aging population. However, this growth is accompanied by structural margin pressure with operating margin declining 2.0 percentage points to 9.6%, suggesting the revenue expansion is coming at elevated cost through competitive pricing, operational investments, or segment mix shift toward lower-margin elderly care operations. The sustainability of the growth model requires demonstration of operational leverage and margin recovery as acquired entities mature.
Cash flow quality represents the most significant structural concern with operating cash flow turning negative at -18.8B yen despite reported net income of 22.7B yen. This -68% cash conversion ratio stems from working capital deterioration, particularly receivables growing 58.7% and days sales outstanding extending to 79 days. The disconnect between accounting profits and cash generation indicates either aggressive revenue recognition practices, structural payment delays in healthcare reimbursement cycles, or challenges in collecting from facility operations. The company's ability to generate positive operating cash flow is fundamental to long-term viability, as the current model requires continuous external financing to fund growth and working capital. Absent meaningful improvement in cash conversion within 2-3 quarters, the business model's sustainability faces material questions.
Financial leverage has escalated to levels warranting careful monitoring with Debt/EBITDA of 6.21x and total interest-bearing debt of 206.8B yen generating 3.4B yen in annual interest expense. The leverage metrics significantly exceed prudent thresholds for healthcare services businesses typically operating at 2.0-3.5x Debt/EBITDA, creating refinancing risk and financial inflexibility. The combination of high leverage and negative operating cash flow creates a dependency on continued credit availability and favorable financing terms. The company must prioritize debt reduction through operational cash flow improvement and asset monetization to restore financial stability, as the current capital structure leaves limited margin for adverse developments in reimbursement policy, operational performance, or credit market conditions. Until leverage normalizes below 4.0x and operating cash flow consistently exceeds net income, the financial risk profile remains elevated.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.